In addition, consecutive sections, comparable to those employed for quantifying Fe and FPN, underwent IHC to assess the presence of the two primary markers associated with AD progression, Tau and Aβ proteins (Figure 5). This evidence concerns the gene MAPT and Alzheimer disease.